Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1

NCT04904406 is registered in ClinicalTrials.gov with Thomas Benfield as lead sponsor.

NCT NCT04904406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04904406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1
Lead sponsor
Thomas Benfield
Phase
Phase 4
Overall status
Completed
Start date
October 22, 2020
Completion date
December 1, 2023
Enrollment
81 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, hiv, hiv cardiomyopathy, hiv infections, hiv lipodystrophy, weight change, body